OKYO Pharma shares are trading higher after the company's OK-101 achieved statistical significance for multiple signs and symptoms of dry eye disease in its first-in-human Phase 2 trial.
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma's shares surged following the announcement that its OK-101 drug achieved statistical significance in treating multiple signs and symptoms of dry eye disease during its Phase 2 trial.
March 22, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OKYO Pharma's stock price is expected to rise in the short term due to positive results from the Phase 2 trial of its OK-101 drug for dry eye disease.
The positive outcome of the Phase 2 trial for OK-101 significantly boosts investor confidence in OKYO Pharma, likely leading to an increase in stock price as the market reacts to the potential of OK-101 in treating dry eye disease.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100